Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Cash flows from operating activities
Net loss	$ (3,628,000)	$ (3,724,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock option compensation expense	1,269,000	1,455,000
Common stock issued for services	319,000	172,000
Bad debt expense	101,000	0
Excess and obsolete inventory	54,000	0
Amortization of right-of-use operating lease assets	90,000	0
Interest expense related to amortization of the discount on note payable	3,000	13,000
Fair value of warrant issued for interest	30,000	0
PPP loan forgiveness	0	(174,000)
Loss on investment in South Korean joint venture	18,000	15,000
Depreciation expense	94,000	28,000
Changes in assets and liabilities:
Accounts receivable	(490,000)	(371,000)
Inventories	(58,000)	(19,000)
Prepaid expenses and other assets	101,000	(85,000)
Deferred revenue	(15,000)	(83,000)
Lease liability, net	(78,000)	0
Customer deposits	(62,000)	30,000
Net cash used in operating activities	(2,363,000)	(2,803,000)
Cash flows from investing activities
Equipment purchases	(332,000)	(164,000)
Net cash used in investing activities	(332,000)	(164,000)
Cash flows from financing activities
Proceeds from sale of common stock	1,497,000	3,267,000
Repayment of note payable and vehicle loan	(55,000)	0
Repayment by Clyra on inventory line of credit	(27,000)	(24,000)
Proceeds from sale of Clyra Medical preferred stock	1,575,000	100,000
Proceeds from Clyra Medical stock option exercise	3,000	0
Net cash provided by financing activities	3,898,000	3,343,000
Net effect of foreign currency translation	(12,000)	(70,000)
Net change in cash	1,191,000	306,000
Cash at beginning of year	1,851,000	962,000
Cash at end of period	3,042,000	1,268,000
Supplemental disclosures of cash flow information
Interest	39,000	11,000
Income taxes	0	0
Short-term lease payments not included in lease liability	43,000	90,000
Non-cash investing and financing activities
Equipment added using capital lease	80,000	0
Right of use	0	433,000
Series A Preferred Stock [Member]
Non-cash investing and financing activities
Preferred Series A dividend	152,000	0
Conversion of Intercompany Receivable into Clyra Shares [Member]
Non-cash investing and financing activities
Allocation of noncontrolling interest	1,860,000	1,129,000
BETI Common Stock [Member]
Cash flows from financing activities
Proceeds from sale of common stock	905,000	0
Entities, Excluding Partially Owned Subsidiary [Member]
Changes in assets and liabilities:
Accounts payable and accrued expenses	(52,000)	(40,000)
Partially Owned Subsidiary [Member]
Changes in assets and liabilities:
Accounts payable and accrued expenses	$ (59,000)	$ (20,000)